Trial Profile

Real world study of sequential switches of pneumococcal conjugate vaccine in Belgium

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
Indications Pneumococcal infections
Focus Pharmacodynamics

Most Recent Events

01 Jan 2021 Results evaluating the evolution of paediatric invasive pneumococcal disease epidemiology with the sequential use of the three conjugate vaccines PCV7, PCV13, and PCV10 in Belgium from 2007 to 2018, published in The Lancet Infectious Diseases
03 Jun 2019 New trial record
16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com